McClarren Financial Advisors Inc. Increases Stake in Johnson & Johnson (NYSE:JNJ)

Posted by on Apr 19th, 2023

McClarren Financial Advisors Inc. grew its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 11.9% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 2,645 shares of the company’s stock after buying an additional 281 shares during the quarter. McClarren Financial Advisors Inc.’s holdings in Johnson & Johnson were worth $467,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. Lincoln Capital Corp lifted its stake in Johnson & Johnson by 15.9% during the third quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after purchasing an additional 183 shares during the last quarter. Ieq Capital LLC lifted its stake in Johnson & Johnson by 5.1% during the third quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after purchasing an additional 6,154 shares during the last quarter. RFG Advisory LLC lifted its stake in Johnson & Johnson by 2.7% during the third quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after purchasing an additional 594 shares during the last quarter. Willis Investment Counsel lifted its stake in Johnson & Johnson by 0.4% during the fourth quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock worth $58,097,000 after purchasing an additional 1,358 shares during the last quarter. Finally, FDx Advisors Inc. lifted its stake in Johnson & Johnson by 0.3% during the third quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock worth $8,237,000 after purchasing an additional 153 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Trading Down 2.8 %

Shares of JNJ stock opened at $161.01 on Wednesday. The business’s fifty day moving average price is $157.50 and its 200 day moving average price is $167.03. Johnson & Johnson has a 1-year low of $150.11 and a 1-year high of $186.69. The firm has a market capitalization of $419.32 billion, a PE ratio of 23.89, a P/E/G ratio of 2.86 and a beta of 0.53. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The firm had revenue of $24.75 billion for the quarter, compared to analyst estimates of $23.61 billion. During the same quarter in the prior year, the company posted $2.67 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.6% on a year-over-year basis. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on JNJ shares. UBS Group started coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective for the company. Morgan Stanley reduced their price objective on Johnson & Johnson from $180.00 to $179.00 and set an “equal weight” rating for the company in a research note on Monday, April 10th. Guggenheim started coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price objective for the company. StockNews.com started coverage on Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Seven analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $173.07.

Insider Buying and Selling

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The stock was sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.